The Fund aims to achieve a total return.
Name | % Net Assets |
---|---|
Bundesschatzanweisungen 0.25 13/12/2013 | 3.0% |
United Kingdom Gilt 4.25 07/12/2040 | 1.8% |
United States Treasury Note/Bond 3.75 15/11/2018 | 1.2% |
United Kingdom Gilt 5.25 07/06/2012 | 0.9% |
GlaxoSmithKline PLC | 0.9% |
Royal Dutch Shell PLC | 0.8% |
United Kingdom Gilt Inflation Linked 2.5 26/07/2016 | 0.8% |
AstraZeneca PLC | 0.7% |
SNS Bank NV 1.735 27/04/2012 | 0.7% |
United Kingdom Gilt 3.75 07/09/2019 | 0.7% |
Key | % Net Assets |
---|---|
Bundesschatzanweisungen 0.25 13/12/2013 | 3.0% |
United Kingdom Gilt 4.25 07/12/2040 | 1.8% |
United States Treasury Note/Bond 3.75 15/11/2018 | 1.2% |
United Kingdom Gilt 5.25 07/06/2012 | 0.9% |
Other | 93.1% |
Date | 09-Apr-2021 |
---|---|
Bid | 108.40p |
Offer | 108.40p |
Currency | GBP |
Change | 0.000p |
% | n/a |
YTD change | 108.40p |
YTD % | n/a |
Fund Inception | 16/09/2002 |
---|---|
Fund Manager | Quentin Fitzsimmons |
TER | 1.26 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £2000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 0.25% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.00 |
Sharpe ratio | 0.11 |
You are here: research